Ignite Creation Date:
2024-05-06 @ 8:26 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06384313
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-01
First Post:
2024-04-22
Brief Title:
Butyrate-enriched Triglyceride and Diabetes Prevention
Sponsor:
Maastricht University Medical Center
Organization:
Maastricht University Medical Center
Study Overview
Official Title:
Prevention of Diabetes With a Novel Butyrate-enriched Triglyceride
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A body of animal studies as well as observational studies in humans demonstrated that butyrate is one SCFA that has pronounced positive effects on body weight control inflammation and insulin resistance Even though the SCFA hexanoate is less researched it has been shown to be involved in anti-inflammatory processes Of note acute human studies showed that fibre-induced metabolic improvements are linked to higher SCFA levels in the systemic circulation It has been shown that a butyratehexanoate-enriched triglyceride oil enhanced systemic butyrate and hexanoate concentrations for a prolonged time Yet it remains to be determined whether a chronic increase in circulating butyrate and hexanoate concentrations translate into long-term benefits In this study it is hypothesized that a chronic increase of butyratehexanoate in the circulation may improve host metabolism and metabolic health by improving adipose tissue function reducing systemic lipid overflow and inflammation thereby increasing peripheral insulin sensitivity in individual with overweightobesity and prediabetes
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None